Gariti P, Alterman A I, Barber W, Bedi N, Luck G, Cnaan A
University of Pennsylvania, School of Medicine, Philadelphia 19104, USA.
Drug Alcohol Depend. 1999 Apr 1;54(2):111-6. doi: 10.1016/s0376-8716(98)00163-x.
This study examined plasma cotinine replacement levels of 56 outpatient smokers administered a 21 mg/day transdermal nicotine patch (Nicoderm CQ ). The percentage of cotinine replacement ranged from 35 to 232% (mean 107%; median 90.5%). Four subject variables were found to be significantly correlated with percentage of cotinine replacement-baseline cotinine level, prior quit attempts, gender, and the Fagerström Tolerance Questionnaire score. A two-variable model consisting of baseline cotinine level and gender provided the most powerful predictor combination. The percentage of cotinine replacement was not predictive of post-treatment smoking. The relatively high levels of cotinine replacement obtained using the Nicoderm CQ 21 mg/day patch suggest cautious use of higher dose treatment with this particular patch.
本研究检测了56名门诊吸烟者使用21毫克/天的尼古丁透皮贴剂（Nicoderm CQ）后的血浆可替宁替代水平。可替宁替代百分比范围为35%至232%（平均107%；中位数90.5%）。发现四个受试者变量与可替宁替代百分比显著相关——基线可替宁水平、既往戒烟尝试、性别以及Fagerström耐受性问卷得分。由基线可替宁水平和性别组成的双变量模型提供了最有力的预测因素组合。可替宁替代百分比不能预测治疗后的吸烟情况。使用21毫克/天的Nicoderm CQ贴剂获得的相对较高的可替宁替代水平表明，使用这种特定贴剂进行高剂量治疗时应谨慎。
